back to US directory
us clinical guidance

Bipolar disorder diagnosis and episode management

VA/DoD-aligned diagnostic triage, phase-specific treatment, maintenance planning and high-risk escalation for adult bipolar disorder.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with suspected or established bipolar I or bipolar II disorder. The 2023 VA/DoD guideline covers diagnostic triage, specialty care, acute mania or hypomania and acute bipolar depression. Pediatric disease, pregnancy-specific prescribing, rapid tranquilization and detailed laboratory or drug-dosing protocols require separate current sources.
sources for this section:VA/DoD bipolar 2023

The Bottom Line

  • Diagnose bipolar disorder from a longitudinal history of distinct mood episodes, change from baseline, associated activation and impairment; mood lability or a screening score alone is insufficient.
  • Ask every patient presenting with depression about prior mania or hypomania, reduced need for sleep, increased activity, impulsivity, psychosis, hospitalization and antidepressant-associated activation.
  • Match treatment to the current phase and severity while considering prior response, suicide risk, comorbidity, interactions, reproductive plans, metabolic burden and patient preference.
  • Continue relapse-prevention care after an acute episode with psychoeducation, adherence support, sleep and routine stabilization, substance-use treatment and early-warning planning.
sources for this section:VA/DoD bipolar 2023

Practical clinical workflow

1
Establish current episode, duration, mixed features, psychosis, agitation, sleep, spending, sexual and driving risk, substance exposure, medical contributors, family history and collateral information with consent.
2
Triage severity and level of care, then confirm bipolar subtype and differential diagnoses such as substance-induced mood disorder, ADHD, trauma, personality disorder, thyroid disease or medication effect.
3
Select a phase-appropriate guideline-supported medicine and psychosocial treatment, complete product-specific baseline assessment and explain expected benefit, monitoring and early warning signs.
4
Measure symptoms and function frequently during acute care, then monitor mood recurrence, adherence, weight and metabolic health, kidney, thyroid, liver, blood count or pregnancy parameters as the chosen medicine requires.
sources for this section:VA/DoD bipolar 2023

Safety boundaries and escalation

  • Severe mania, psychosis, catatonia, inability to sleep or eat, dangerous impulsivity, aggression, suicidal intent or inability to care for self or dependents requires urgent psychiatric assessment and often a higher level of care.
  • Do not treat possible bipolar depression as routine unipolar depression without assessing mania history; antidepressant strategy depends on diagnosis, phase and concurrent mood-stabilizing treatment.
  • Lithium and other bipolar medicines have distinct toxicity, interaction, pregnancy and organ-monitoring requirements; vomiting, dehydration, neurologic change or a major interacting medicine can require urgent review.
  • Do not stop maintenance medication abruptly because of pregnancy, adverse effects or apparent recovery; urgently coordinate a safer individualized plan and current reproductive-risk counseling.
sources for this section:VA/DoD bipolar 2023VA/DoD suicide risk 2024

Localization

VA/DoD supplies a current US federal framework, while involuntary-care law, psychiatric-bed access, monitoring coverage and formularies vary by state and payer. FDA indications and warnings remain product-specific.
sources for this section:VA/DoD bipolar 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for Management of Bipolar DisorderVersion 1.0 (2023); official guideline page updated 2025-04-18 路 published 2023-05-01 路 updated 2025-04-18 路 accessed 2026-08-20
    view source
  2. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide2024 guideline; official guideline page checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.